{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:24:35Z","timestamp":1789403075306,"version":"build-2803163510"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Neutrophils are the most common type of white blood cell in the body, acting as crucial mediators of innate immunity. They initiate immune responses against invading microorganisms and threats like cancerous cells. Neutrophil infiltration is observed across inflammatory and autoimmune diseases and many cancers. Neutrophils orchestrate innate and adaptive immune responses to return the body to homeostasis, including after infections and preventing the development of tumours. While both protective and deleterious functions of neutrophils have been reported, this dual functionality reflects the heterogeneity of neutrophil subsets. Previously, neutrophils short lifespan resulted in their underappreciation. Recent advances in technology and methodology have drastically increased understanding of neutrophil biology, heterogeneity and plasticity, leading to a plethora of discoveries around the therapeutic potential of neutrophils, both through their direct cytotoxic effects to remove deleterious populations and through their ability to modulate other components of immunity. How to achieve this therapeutically with a rapidly-turned over population has proven elusive until now. This review highlights physiological and patho-physiological activities of neutrophil populations and their therapeutic potential and challenges. Recent and ongoing efforts to target or exploit neutrophil-type populations therapeutically have included engager-type antibody-based reagents and \u2018off-the-shelf\u2019 allogeneic cell therapy with and \u2018Immuno-Modulatory Alpha Neutrophils\u2019 (IMANs).<\/jats:p>","DOI":"10.3389\/fimmu.2026.1760161","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:39:05Z","timestamp":1776832745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Physiological, patho-physiological, and potential therapeutic roles for neutrophils in cancer &amp; beyond"],"prefix":"10.3389","volume":"17","author":[{"given":"Connor","family":"McGarrity-Cottrell","sequence":"first","affiliation":[{"name":"Lift Biosciences, London Bioscience Innovation Centre","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife","family":"McGinley","sequence":"additional","affiliation":[{"name":"Lift Biosciences, London Bioscience Innovation Centre","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Becares","sequence":"additional","affiliation":[{"name":"Lift Biosciences, London Bioscience Innovation Centre","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Lich","sequence":"additional","affiliation":[{"name":"Lift Biosciences, London Bioscience Innovation Centre","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Roper","sequence":"additional","affiliation":[{"name":"Lift Biosciences, London Bioscience Innovation Centre","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Florence","sequence":"additional","affiliation":[{"name":"Lift Biosciences, London Bioscience Innovation Centre","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihil","family":"Patel","sequence":"additional","affiliation":[{"name":"Lift Biosciences, London Bioscience Innovation Centre","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Exley","sequence":"additional","affiliation":[{"name":"Lift Biosciences, London Bioscience Innovation Centre","place":["London, United Kingdom"]},{"name":"Department of Life Sciences, Imperial College","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: Differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.4MIR0220-574RR","article-title":"Neutrophils at the crossroads of innate and adaptive immunity","volume":"108","author":"Rosales","year":"2020","journal-title":"J Leukocyte Biol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat4579","article-title":"Neutrophils: New insights and open questions","volume":"3","author":"Ley","year":"2018","journal-title":"Sci Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nri1785","article-title":"Neutrophils and immunity: challenges and opportunities","volume":"6","author":"Nathan","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd005339.pub2","article-title":"Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction","volume":"2015","author":"Estcourt","year":"2015","journal-title":"Cochrane Database Systematic Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2017.08.012","article-title":"Granulocyte transfusions: A concise review for practitioners","volume":"19","author":"Gea-Banacloche","year":"2017","journal-title":"Cytotherapy"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02228-7","article-title":"Bidirectional role of neutrophils in tumor development","volume":"24","author":"Luyang","year":"2025","journal-title":"Mol Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/intimm\/dxac055","article-title":"Neutrophils in homeostasis and tissue repair","volume":"34","author":"Shim","year":"2022","journal-title":"Int Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nri3024","article-title":"Neutrophils in the activation and regulation of innate and adaptive immunity","volume":"11","author":"Mantovani","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.20220011","article-title":"Neutrophil phenotypes and functions in cancer: A consensus statement","volume":"219","author":"Quail","year":"2022","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-024-02004-z","article-title":"Neutrophils in Cancer immunotherapy: friends or foes","volume":"23","author":"Huang","year":"2024","journal-title":"Mol Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41392-025-02242-7","article-title":"Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity","volume":"10","author":"Zhou","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Institute"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.734188","article-title":"The recruitment of neutrophils to the tumor microenvironment is regulated by multiple mediators","volume":"12","author":"Sengupta","year":"2021","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \u201cN1\u201d versus \u201cN2\u201d TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290886","article-title":"TGF-\u03b21 activates neutrophil signaling and gene expression but not migration","volume":"18","author":"Hein","year":"2023","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00532","article-title":"An attempt to polarize human neutrophils toward N1 and N2 phenotypes in vitro","volume":"11","author":"Ohms","year":"2020","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S347777","article-title":"Tumor-infiltrating PD-L1+ neutrophils induced by GM-CSF suppress T cell function in laryngeal squamous cell carcinoma and predict unfavorable prognosis","volume":"15","author":"Tang","year":"2022","journal-title":"J Inflammation Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1136\/gutjnl-2016-313075","article-title":"Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway","volume":"66","author":"Wang","year":"2017","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4227","article-title":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice","volume":"361","author":"Albrengues","year":"2018","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-014-1683-3","article-title":"Neutrophil extracellular traps in cancer progression","volume":"71","author":"CoolsLartigue","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1186\/s12967-022-03723-x","article-title":"Integrating single-cell RNA-seq to construct a neutrophil prognostic model for predicting immune responses in non-small cell lung cancer","volume":"20","author":"Pang","year":"2022","journal-title":"J Transl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ccell.2023.01.002","article-title":"Neutrophil-activating therapy for the treatment of cancer","volume":"41","author":"Linde","year":"2023","journal-title":"Cancer Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","article-title":"T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants","volume":"186","author":"Hirschhorn","year":"2023","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","article-title":"A neutrophil response linked to tumor control in immunotherapy","volume":"186","author":"Gungabeesoon","year":"2023","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2023.12.005","article-title":"Interferon stimulated neutrophils as a predictor of immunotherapy response","volume":"42","author":"Benguigui","year":"2024","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052929","article-title":"Neutrophils at the crossroads: unraveling the multifaceted role in the tumor microenvironment","volume":"25","author":"Awasthi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201902467R","article-title":"Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis","volume":"34","author":"Shaul","year":"2020","journal-title":"FASEB J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1216585","article-title":"Machine learning-based integration develops a neutrophil-derived signature for improving outcomes in hepatocellular carcinoma","volume":"14","author":"Gong","year":"2023","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2023.03.008","article-title":"Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-\u03b2 activation","volume":"41","author":"Mousset","year":"2023","journal-title":"Cancer Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1038\/s41467-021-23086-z","article-title":"Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer","volume":"12","author":"Shinde-Jadhav","year":"2021","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01467","article-title":"LongTerm followUp of antiCD19 chimeric antigen receptor TCell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12935-025-03938-0","article-title":"Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions","volume":"25","author":"Zhu","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B36","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41467-023-44648-3","article-title":"Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02063","article-title":"Excessive neutrophils and neutrophil extracellular traps in COVID-19","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010728","article-title":"Longitudinal plasma proteomics in CAR T\u2013cell therapy patients implicates neutrophils and NETosis in the genesis of CRS","volume":"8","author":"Flora","year":"2024","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002303","article-title":"Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma","volume":"9","author":"Brammer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12916-025-03968-5","article-title":"Elevated CD10- neutrophils correlate with non-response and poor prognosis of CD19 CAR T-cell therapy for B-cell acute lymphoblastic leukemia","volume":"23","author":"Zhu","year":"2025","journal-title":"BMC Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073636","article-title":"Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases","volume":"23","author":"Buonacera","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03015-3","article-title":"Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer","volume":"132","author":"Li","year":"2025","journal-title":"Br J Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-844548","article-title":"Neutrophil plasticity in the tumor microenvironment","volume":"134","author":"Giese","year":"2019","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1016\/j.celrep.2018.05.082","article-title":"Neutrophils kill antibody-opsonized cancer cells by trogoptosis","volume":"23","author":"Matlung","year":"2018","journal-title":"Cell Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101581","article-title":"Therapeutic exploitation of neutrophils to fight cancer","volume":"57","author":"Gruijs","year":"2021","journal-title":"Semin Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217820","article-title":"The neutrophil: the underdog that packs a punch in the fight against cancer","volume":"21","author":"Avtenyuk","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002581","article-title":"Targeting Fc\u03b1RI on polymorphonuclear cells induces tumour cell killing through autophagy","volume":"187","author":"Bakema","year":"2011","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/imr.12739","article-title":"Neutrophils and IgA: Fc\u03b1RI as an effector receptor for immunity and immunotherapy","volume":"273","author":"Van Egmond","year":"2019","journal-title":"Immunol Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00704","article-title":"Potent Fc receptor signalling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG","volume":"10","author":"Brandsma","year":"2019","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1232","article-title":"An anti-EGFR IgA that displays improved pharmacokinetics and myeloid effector cell engagement in vivo","volume":"76","author":"Lohse","year":"2016","journal-title":"Cancer Research"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.9.5472","article-title":"Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors","volume":"174","author":"Otten","year":"2005","journal-title":"Journal of Immunology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/antib9040070","article-title":"Fc engineering strategies to advance IgA antibodies as therapeutic agents","volume":"9","author":"Van Tetering","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/imr.12343","article-title":"Fc\u03b3 receptor pathways during active and passive immunization","volume":"268","author":"Bournazos","year":"2015","journal-title":"Immunol Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1380142","article-title":"CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy","volume":"7","author":"Li","year":"2017","journal-title":"OncoImmunology"},{"key":"B58","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.3390\/cancers14215297","article-title":"Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review","volume":"14","author":"Guo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1393925","article-title":"Neutrophil-to-lymphocyte ratio as a predictive biomarker for hyperprogressive disease mediated by immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"15","author":"Pei","year":"2024","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002242","article-title":"Neutrophils in the era of immune checkpoint blockade","volume":"9","author":"Faget","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142507","article-title":"The multifaceted role of neutrophils in NSCLC in the era of immune checkpoint inhibitors","volume":"16","author":"Miao","year":"2024","journal-title":"Cancers"},{"key":"B62","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13046-025-03555-9","article-title":"Bridging innate and adaptive tumor immunity: cGAS\u2013STING pathway activation to potentiate immune checkpoint blockade","volume":"44","author":"Li","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41590-024-02029-y","article-title":"The heterogeneity of neutrophils in cancer and its implication for therapeutic targeting","volume":"26","author":"Eruslanov","year":"2025","journal-title":"Nat Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01739","article-title":"Open-label Phase II prospective, randomized, controlled study of Romyelocel-L myeloid progenitor cells to reduce infection during induction chemotherapy for acute myeloid leukemia","volume":"39","author":"Desai","year":"2021","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011719","article-title":"Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-023-00662-1","article-title":"Omidubicel: first approval","volume":"27","author":"Heo","year":"2023","journal-title":"Mol Diagnosis Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.01.031","article-title":"Multicenter long-term follow-up of allogeneic hematopoietic cell transplantation with Omidubicel: a pooled analysis of five prospective clinical trials","volume":"29","author":"Lin","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.04.005","article-title":"Omidubicel transplantation for hematologic malignancies: results of a multicenter expanded access program","author":"Horwitz","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12015-025-10991-9","article-title":"Opening new horizons: advanced hematopoietic stem cell expansion strategies bridging cord blood therapy from bench to bedside","volume":"21","author":"Li","year":"2025","journal-title":"Stem Cell Rev Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-SITC2025.0645","article-title":"IMANs: a transformative allogeneic neutrophil cell therapy for rejuvenating innate immunity and overcoming treatment resistance in solid tumours","volume":"13","author":"McGinley","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.04.033","article-title":"IMANS: a transformative solution for overcoming challenges of solid tumour immunotherapy and rejuvenating innate immunity, with broad implications for oncology and beyond","volume":"27","author":"Blyth","year":"2025","journal-title":"Cytotherapy"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5511-12.2013","article-title":"Neutrophils express oncomodulin and promote optic nerve regeneration","volume":"33","author":"Kurimoto","year":"2013","journal-title":"J Neurosci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313535","article-title":"CD177+ neutrophils as functionally activated neutrophils negatively regulate IBD","volume":"67","author":"Zhou","year":"2018","journal-title":"Gut"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay5356","article-title":"Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy","volume":"369","author":"Binet","year":"2020","journal-title":"Science"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00813-0","article-title":"A new neutrophil subset promotes CNS neuron survival and axon regeneration","volume":"21","author":"Sas","year":"2020","journal-title":"Nat Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"6157","DOI":"10.1038\/s41467-021-26244-5","article-title":"Antibiotic-chemoattractants enhance neutrophil clearance of Staphylococcus aureus","volume":"12","author":"Payne","year":"2021","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105035","article-title":"Neutrophil-mediated delivery of the combination of colistin and azithromycin for the treatment of bacterial infection","volume":"25","author":"Gao","year":"2022","journal-title":"iScience"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326484","article-title":"What good can neutrophils do in UC","volume":"71","author":"Salas","year":"2022","journal-title":"Gut"},{"key":"B79","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00262-024-03695-5","article-title":"Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells","volume":"73","author":"Favaretto","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"B81","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/01902140903131200","article-title":"Inhibition of myristoylated alanine-rich C kinase substrate (MARCKS) protein inhibits ozone-induced airway neutrophilia and inflammation","volume":"36","author":"Damera","year":"2010","journal-title":"Exp Lung Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12931-025-03194-w","article-title":"MARCKS protein is a potential target in a naturally occurring equine model of neutrophilic asthma","volume":"26","author":"Conley","year":"2025","journal-title":"Respir Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19336918.2023.2233204","article-title":"A myristoylated alanine-rich C-kinase substrate (MARCKS) inhibitor peptide attenuates neutrophil outside-in \u03b22-integrin activation and signaling","volume":"17","author":"Conley","year":"2023","journal-title":"Cell Adh Migr"},{"key":"B84","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s11033-025-11027-8","article-title":"MARCKS N-terminal sequence-derived inhibitor peptides impair monocytic ROS production and migration via MARCKS-independent effects","volume":"52","author":"K\u00fchl","year":"2025","journal-title":"Mol Biol Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1760161\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:39:12Z","timestamp":1776832752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1760161\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":84,"alternative-id":["10.3389\/fimmu.2026.1760161"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1760161","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1760161"}}